Here's your news in US review and approval news in brief: AbbVie Inc. and Genentech Inc.'s Venclexta (venetoclax tablets) has become the seventh drug to score an approval under the FDA's Real-Time Oncology Review pilot for significant supplemental applications.
Several other companies reeled in supplemental approvals as well, including Regeneron Pharmaceuticals Inc.'s eye drug Eylea (aflibercept) for diabetic retinopathy and Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?